Abstract
Antiresorptive drugs: Bisphosphonates (BPs) and Monoclonal Antibodies: Denosumab (DS) are known to suppress osteoclastic activity, affecting the expression of the RANKL (Kappa β Nuclear Activation Receptor), which corresponds to an osteoblastic differentiation factor and which is secreted by said cells, being responsible for inducing reabsorption by osteoclasts. Under certain circumstances, those medications may induce the development of Maxillary Osteonecrosis (MRONJ).The paper is aimed to share our experience of MRONJ treatment using minimally invasive therapies (including washes and antibiotics) that does not expand the necrotic bed volumetrically and provide non-recurrent resolution of the lesion. The patients we described were on long-term therapy either with BPs or DS.Conclusion: Interaction between health professional is essential for MRONJ prevention. The therapeutics consolidated in non-invasive maneuvers, and the manipulation of bone tissue with close follow up allows to avoid spread to deep planes. The pathological process could be successfully treated, and it is not necessary to suspend antiresorptive medications.
Highlights
Maxillary Osteonecrosis (MRONJ) is a sequel to the treatment of the last generation BPs administered intravenously, Medication-Related Osteonecrosis of the Jaw (MRONJ) induced by orally supplied BPs exists, it is less frequent, like those developed by DS
From the results found and from those published in the bibliography, it appears that the interaction between health professionals is essential since the prevention of MRONJ is better than the treatment
Prior dental evaluation of patients is recommended to carry out dental interventions before establishing chronic treatment with antiresorptive drugs
Summary
Maxillary Osteonecrosis (MRONJ) is a sequel to the treatment of the last generation BPs administered intravenously, MRONJ induced by orally supplied BPs exists, it is less frequent, like those developed by DS. Preventive measures should be implemented, including dental consultation before starting antiresorptive drug therapy and post-surgical control of oral interventions involving bone tissue.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
